Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.36 |
| ▸ | ITGAV | P06756 | 7/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.35 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8226890 | 0.93 | CTSL (0.73) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL8221738 | 0.93 | CTSL (0.69) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL8227164 | 0.93 | CTSL (0.69) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL14434277 | 0.91 | CTSL (0.70) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL14434101 | 0.91 | CTSL (0.74) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL14434171 | 0.91 | CTSL (0.70) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL8354015 | 0.91 | CTSL (0.68) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL8230343 | 0.90 | CTSL (0.67) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL8242592 | 0.90 | CTSL (0.58) | CTSLDRD1PTGS1PDE4AITGB3 | |
| SCHEMBL8227193 | 0.90 | CTSL (0.58) | CTSLDRD1PTGS1PDE4AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7262268-B2 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | CTSL 187/4885DRD1 3225/4885PTGS1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.